In a first for the Canadian cannabis market, a suspended sales licence for a privately owned licensed producer has been reinstated by Health Canada.

On Wednesday (October 23), the Winnipeg-based cannabis producer Bonify announced it would now be able to move its products back onto shelves after having its license revoked in February due to concerns about health and public safety.

In December 2018, Bonify had two separate recalls of its dried cannabis products for labeling issues and failing to meet “microbial and chemical contaminant limits as specified by the Good Production Practices requirements of the Cannabis Regulations,” according to one of the recall alerts.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Health Canada spokesperson Eric Morrissette said in a statement that along with the contamination issues, Bonify was found to be processing and distributing product from an illegal source to stores in Saskatchewan.

As a result, the Manitoba Liquor and Lotteries Corporation, the firm’s home province cannabis wholesaler, and the Liquor, Gaming and Cannabis Authority of Manitoba, the provincial cannabis regulator, suspended the sale of Bonify’s products.

Now that Bonify’s license has been reinstated, one public cannabis player is raising its hand to indicate its own involvement in the license change.

RavenQuest BioMed (CSE:RQB,OTCQB:RVVQF), which has its hand in consultancy work for the marijuana industry, was hired to provide “the necessary direction and corrective action” to improve Bonify’s operations, according to the company.

George Robinson, CEO of RavenQuest and current interim CEO of Bonify, told the Investing News Network (INN) the 10 month process of bringing Bonify back up to regulatory compliance started with rejigging the company culture to both reinforce awareness and that following the operating standards was the main priority.

The process involved adjusting Bonify’s standard operating procedure (SOP) documents to reflect this planned culture shift.

“The standard operating procedures that were in place prior to (the license suspension) occurring … were actually pretty solid. But there was (no) additional steps in there to say ‘If you feel that you’re being pressured to do something that’s outside of the SOP or outside the regulations, call this person or call Health Canada,’” Robinson told INN.

Robinson added that Bonify voluntarily suspended its sales license in December 2018 ahead of Health Canada’s initial inspection when the federal agency formally revoked the license.

The executive said RavenQuest helped Bonify’s core management team to identify the areas in which the company was failing and who was responsible for the failures, putting measures in place to prevent senior management from making choices that could lead to non-compliant operations.

“The changes in there were to give the employees … escape routes out … if they feel they’re being pressured to do something,” Robinson told INN.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

RavenQuest expresses confidence in new compliance strategy, offers services to non-compliant firms

The company touted it now has the roadmap for bringing non-compliant cannabis operators up to Health Canada standards and it is open to helping other cannabis firms dealing with license suspensions.

Robinson said RavenQuest now has a process that will allow companies to demonstrate to Health Canada the changes put in place in the event of a license suspension. The new process involves acting out specific operations to show the regulator its standards are up to scratch.

He said that, as a part of the overhaul of Bonify’s operations, vendor qualifications were also established to prevent illicit product from entering Bonify’s facilities and from being distributed to other parties, meaning it could take four to six weeks before its products are back on the shelves.

Perhaps the best known non-compliance issue in the cannabis space was the CannTrust Holdings (NYSE:CTST,TSX:TRST) debacle.

CannTrust had its production and sales license suspended in September after an investigation revealed the Ontario-based producer was growing cannabis illegally in unlicensed rooms.

The suspension followed a particularly trying summer for the cannabis firm during which it was found that high level executives, including former CEO Peter Aceto and former Chairman Eric Paul, were aware of the illegal operations.

Agrima Botanicals, subsidiary of Ascent Industries, also had its licenses revoked in July after Health Canada found that “unauthorized activities” took place at the company, CBC reported.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here:

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less


Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (FRA: D2EP) (“Adastra”, or the “Company”) is pleased to announce that it has retained Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for Adastra and to broaden the Company’s reach within the investment community.

Keep reading... Show less